- Home
- WNEB vs CRVS Comparison
WNEB vs CRVS Comparison
Compare WNEB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | CRVS |
|---|---|---|
| Founded | 1853 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.3M | 1.7B |
| IPO Year | 2001 | 2016 |
Fundamental Metrics
Financial Performance| Metric | WNEB | CRVS |
|---|---|---|
| Price | $12.70 | $15.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.50 | ★ $28.20 |
| AVG Volume (30 Days) | 66.1K | ★ 1.0M |
| Earning Date | 04-28-2026 | 06-26-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | 33.93 | ★ 48.04 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | $16.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.63 | $2.54 |
| 52 Week High | $14.52 | $26.95 |
Technical Indicators
Market Signals| Indicator | WNEB | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 42.27 |
| Support Level | $12.65 | $6.65 |
| Resistance Level | $13.73 | $18.73 |
| Average True Range (ATR) | 0.42 | 0.94 |
| MACD | -0.02 | -0.29 |
| Stochastic Oscillator | 42.47 | 24.64 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).